<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02783404</url>
  </required_header>
  <id_info>
    <org_study_id>Univ of Santiago de Compostela</org_study_id>
    <nct_id>NCT02783404</nct_id>
  </id_info>
  <brief_title>An Oral Amoxicillin-Clavulanate Regimen to Prevent Bacteremia Following Dental Procedures</brief_title>
  <official_title>An Oral Amoxicillin-Clavulanate Regimen to Prevent Bacteremia Following</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Santiago de Compostela</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hospital Clinico Universitario de Santiago</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Santiago de Compostela</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Although controversy exists regarding the efficacy of antibiotic prophylaxis for patients at&#xD;
      risk of infective endocarditis, expert committees continue to publish recommendations for&#xD;
      antibiotic prophylactic regimens. Recently, the investigators have evaluated the efficacy of&#xD;
      the intravenous administration of 1000/200 mg of amoxicillin/clavulanate for the prevention&#xD;
      of bacteraemia following dental extractions. The results of this study suggest that is highly&#xD;
      effective, and that it might be considered a first-line choice for patients at high-risk for&#xD;
      infective endocarditis who undergo dental procedures and for whom antimicrobial prophylaxis&#xD;
      is recommended. This new project aims to evaluate the effectiveness of oral&#xD;
      amoxicillin/clavulanate in preventing post-dental extraction bloodstream infection.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PURPOSE: Despite the controversy about the risk of developing bacterial endocarditis of oral&#xD;
      origin, numerous Expert Committees in different countries continue to publish prophylactic&#xD;
      regimens. To date, the literature is unclear about the role of antimicrobial prophylaxis in&#xD;
      the prevention of bacteremia following dental procedures. The aim of this study is to&#xD;
      evaluate the efficacy of prophylactic dosage with oral amoxicillin-clavulanate (AMX-CLV) in&#xD;
      the prevention of bacteremia following dental extractions.&#xD;
&#xD;
      SELECTION OF THE STUDY GROUP AND STUDY DESIGN: The study group will comprise patients who,&#xD;
      for behavioral reasons (autism, learning disabilities, phobias, etc.), will undergo dental&#xD;
      extractions under general anesthesia in the Santiago de Compostela University Hospital&#xD;
      (Santiago de Compostela, Spain). The following exclusion criteria will be applied: age under&#xD;
      18 years; body weight under 40 kg; receipt of antibiotics in the previous 3 months; routine&#xD;
      use of oral antiseptics; a history of allergy or intolerance to AMX or CLV; any type of&#xD;
      congenital or acquired immunodeficiency; or any known risk factor for bacterial endocarditis.&#xD;
      By applying these criteria, 150 patients will be selected and will be randomly distributed&#xD;
      into 3 study groups: control group (receiving no prophylaxis), AMX-CLV group (receiving 2&#xD;
      g/125 mg oral AMX-CLV), and AMX group (receiving 2 g oral AMX).&#xD;
&#xD;
      COLLECTION OF SAMPLES FOR BLOOD CULTURE: To determine the prevalence of bacteremia, a&#xD;
      peripheral venous blood sample (10 ml) will be drawn from each patient at the baseline&#xD;
      (before any dental manipulation but after nasotracheal intubation) and 30 s, 15 min, and 1 h&#xD;
      after the final dental extraction. Samples will be inoculated in BACTEC plus (Becton&#xD;
      Dickinson and Company, Sparks, MD) aerobic and anaerobic blood culture bottles, and will be&#xD;
      processed in the Bactec 9240 (Becton Dickinson).&#xD;
&#xD;
      MICROBIOLOGICAL ANALYSIS OF BLOOD CULTURES: A Gram stain will be performed on each positive&#xD;
      blood culture. The positive blood cultures in the aerobic media will be subcultured on blood&#xD;
      agar and chocolate agar in an atmosphere of 5 to 10% carbon monoxide and on MacConkey agar&#xD;
      under aerobic conditions. The same protocol will be used for the positive blood cultures in&#xD;
      the anaerobic media, with subculture on Schaedler agar and incubation in an anaerobic&#xD;
      atmosphere. The bacteria isolated will be identified by using the battery of biochemical&#xD;
      tests provided with the Vitek system for Gram-positive bacteria, Neisseria spp., Haemophilus&#xD;
      spp., and obligate anaerobic bacteria. The viridans group streptococci will be classified&#xD;
      into five groups, the Streptococcus mitis, S. anginosus, S. salivarius, S. mutans, and S.&#xD;
      bovis groups, by applying the Ruoff criteria. Facklam's criteria will be used to identify&#xD;
      unusual Streptococcus spp. and other gram-positive cocci in chains.&#xD;
&#xD;
      The subculture and further identification of the isolated bacteria will be performed by&#xD;
      conventional microbiological techniques. The collection, handling, and transport of the blood&#xD;
      samples for blood culture will be performed according to the recommendations of the Spanish&#xD;
      Society of Infectious Diseases and Clinical Microbiology.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 27, 2017</start_date>
  <completion_date type="Anticipated">December 27, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 27, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bacteremia in participants receiving a prophylactic dosage with oral amoxicillin-clavulanate</measure>
    <time_frame>Changes from baseline in prevalence of bacteremia at 30 seconds, 15 minutes and 1 hour after the final dent</time_frame>
    <description>Positive cultures</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bacteremia in participants receiving a prophylactic dosage with oral amoxicillin</measure>
    <time_frame>Changes from baseline in prevalence of bacteremia at 30 seconds, 15 minutes and 1 hour after the final dental extraction</time_frame>
    <description>Positive cultures</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bacteremia in participants receiving no prophylaxis</measure>
    <time_frame>Changes from baseline in prevalence of bacteremia at 30 seconds, 15 minutes and 1 hour after the final dental extraction</time_frame>
    <description>Positive cultures</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Bacteraemia</condition>
  <condition>Endocarditis</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Receiving no prophylaxis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Amoxicillin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Receiving 2 gr oral Amoxicillin before any dental manipulation and following endotracheal intubation&#xD;
Intervention: Drug: Amoxicillin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Amoxicillin-Potassium Clavulanate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Receiving 2gr/125 mg oral Amoxicillin-Potassium Clavulanate before any dental manipulation and following endotracheal intubation&#xD;
Intervention: Drug: Amoxicillin-Potassium Clavulanate</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amoxicillin</intervention_name>
    <description>Receiving 2 gr oral Amoxicillin before dental any manipulation and following endotracheal intubation</description>
    <arm_group_label>Amoxicillin</arm_group_label>
    <other_name>Amoxicillin (generic drug)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amoxicillin-Potassium Clavulanate</intervention_name>
    <description>Receiving 2 gr/125 mg oral Amoxicillin-Potassium Clavulanate before any dental manipulation and following endotracheal intubation&#xD;
Intervention: Drug: Amoxicillin-Potassium Clavulanate</description>
    <arm_group_label>Amoxicillin-Potassium Clavulanate</arm_group_label>
    <other_name>Amoxicillin-Potassium Clavulanate (generic drug)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects must have at least 10 teeth&#xD;
&#xD;
          -  Subjects must have the need for a dental extraction under general anesthesia (for&#xD;
             behavioral reasons)&#xD;
&#xD;
          -  Subjects will be recruited regardless of the extent and severity of their dental&#xD;
             and/or periodontal disease&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age under 18 years&#xD;
&#xD;
          -  Body weight under 40 kg&#xD;
&#xD;
          -  Receipt of antibiotics in the previous 3 months&#xD;
&#xD;
          -  Routine use of oral antiseptics&#xD;
&#xD;
          -  A history of allergy or intolerance to amoxicillin&#xD;
&#xD;
          -  A history of allergy or intolerance to chlorhexidine&#xD;
&#xD;
          -  A history of allergy or intolerance to amoxicillin-clavulanate&#xD;
&#xD;
          -  Any type of congenital or acquired immunodeficiency&#xD;
&#xD;
          -  Any known risk factor for bacterial endocarditis&#xD;
&#xD;
          -  Any known risk factor for prolonged bleeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pedro Diz, MD, DDS, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Santiago de Compostela University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jacobo Limeres, DDS, PhD</last_name>
    <phone>+34881812344</phone>
    <phone_ext>12344</phone_ext>
    <email>jacobo.limeres@usc.es</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Clinico Universitario de Santiago</name>
      <address>
        <city>Santiago de Compostela</city>
        <state>A Coruña</state>
        <zip>15782</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pedro Diz, MD,DD,PhD</last_name>
      <phone>+34881812344</phone>
      <phone_ext>12344</phone_ext>
      <email>pedro.diz@usc.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Santiago de Compostela University Hospital</name>
      <address>
        <city>Santiago de Compostela</city>
        <state>Coruña</state>
        <zip>15782</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pedro Diz, MD, DDS, PHD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Diz Dios P. Infective endocarditis prophylaxis. Oral Dis. 2014 May;20(4):325-8. doi: 10.1111/odi.12221. Epub 2014 Jan 13. Review.</citation>
    <PMID>24373017</PMID>
  </reference>
  <results_reference>
    <citation>Valdés C, Tomás I, Alvarez M, Limeres J, Medina J, Diz P. The incidence of bacteraemia associated with tracheal intubation. Anaesthesia. 2008 Jun;63(6):588-92. doi: 10.1111/j.1365-2044.2008.05449.x.</citation>
    <PMID>18477269</PMID>
  </results_reference>
  <results_reference>
    <citation>Piñeiro A, Tomás I, Blanco J, Alvarez M, Seoane J, Diz P. Bacteraemia following dental implants' placement. Clin Oral Implants Res. 2010 Sep;21(9):913-8. doi: 10.1111/j.1600-0501.2010.01928.x.</citation>
    <PMID>20701619</PMID>
  </results_reference>
  <results_reference>
    <citation>Diz Dios P, Tomás Carmona I, Limeres Posse J, Medina Henríquez J, Fernández Feijoo J, Alvarez Fernández M. Comparative efficacies of amoxicillin, clindamycin, and moxifloxacin in prevention of bacteremia following dental extractions. Antimicrob Agents Chemother. 2006 Sep;50(9):2996-3002.</citation>
    <PMID>16940094</PMID>
  </results_reference>
  <results_reference>
    <citation>Limeres Posse J, Álvarez Fernández M, Fernández Feijoo J, Medina Henríquez J, Lockhart PB, Chu VH, Diz Dios P. Intravenous amoxicillin/clavulanate for the prevention of bacteraemia following dental procedures: a randomized clinical trial. J Antimicrob Chemother. 2016 Jul;71(7):2022-30. doi: 10.1093/jac/dkw081. Epub 2016 Mar 29.</citation>
    <PMID>27029851</PMID>
  </results_reference>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>May 22, 2016</study_first_submitted>
  <study_first_submitted_qc>May 25, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 26, 2016</study_first_posted>
  <last_update_submitted>April 27, 2021</last_update_submitted>
  <last_update_submitted_qc>April 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Santiago de Compostela</investigator_affiliation>
    <investigator_full_name>Pedro DIz DIos</investigator_full_name>
    <investigator_title>MD, DDS, PhD, Professor</investigator_title>
  </responsible_party>
  <keyword>bacteraemia</keyword>
  <keyword>endocarditis</keyword>
  <keyword>antibiotic prophylaxis</keyword>
  <keyword>dentistry</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bacteremia</mesh_term>
    <mesh_term>Endocarditis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amoxicillin</mesh_term>
    <mesh_term>Clavulanic Acid</mesh_term>
    <mesh_term>Clavulanic Acids</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>IPD will be available on request</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>By the end of the study (for 1 year)</ipd_time_frame>
    <ipd_access_criteria>On request</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

